Postpartum management of hypertension and effect on readmission rates.
Todd Lovgren, Brendan Connealy, Ruofan Yao...
https://pubmed.ncbi.nlm.nih.gov/34757235/Actively Recruiting
Led by Nebraska Methodist Health System · Updated on 2024-04-12
600
Participants Needed
1
Research Sites
30 weeks
Total Duration
The trial investigates postpartum hypertension management by comparing the risk of hospital readmission and hypertensive complications in patients treated with Labetalol versus Nifedipine. It is a randomized controlled trial enrolling patients admitted for delivery at 24 weeks gestation or later who have hypertension defined by specific blood pressure thresholds. The study aims to evaluate which medication better controls postpartum hypertension and reduces readmission risks. Participants are randomly assigned to one of two treatment groups. In the Nifedipine arm, patients start on extended-release Nifedipine 30mg twice daily, with dose escalation by the primary provider up to 120mg daily. If hypertension persists, Labetalol is added. In the Labetalol arm, patients start at 200mg three times daily, with escalation up to 2400mg daily if higher doses are not tolerated due to bradycardia, Nifedipine is added. Patients are monitored for side effects and signs of low blood pressure, and hospitalization is not extended solely for study purposes. Participants undergo outpatient follow-up as directed by their care provider. At six months, researchers contact patients to check for hospital readmissions and review medical records for emergency evaluations or readmissions. The primary outcome is hospital readmission within six months. Secondary outcomes include medication failure and changes or discontinuation within six months. Safety is overseen by a monitoring board reviewing data every six months, with study termination planned if significant differences arise.
CONDITIONS
Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial
T
Todd Lovgren, MD
J
Joshua Dahlke, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Nebraska Methodist Health System
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Labetalol Oral Tablet | Nifedipine ER |
|---|---|---|
| What it is | Labetalol oral tablets, a beta-blocker, are used for lowering blood pressure in patients after delivery. | Nifedipine extended-release tablets, a calcium channel blocker, are administered to control postpartum hypertension. |
| Role in trial | One of two active comparator treatments assigned for postpartum hypertension. | Comparator treatment directly randomized against Labetalol for postpartum hypertension. |
| Primary use in care | Lowering blood pressure in postpartum patients with hypertension after delivery. | Controlling high blood pressure in postpartum patients following pregnancy. |
| How it is given | Given as oral tablets, dose escalated by provider to achieve target blood pressure. | Taken as oral extended-release tablets, with dosing adjusted to reach normal blood pressure. |
| Evidence status | Labetalol is supported by published studies and registry evidence as an option for managing hypertension after delivery. | Published clinical studies and registry evidence support Nifedipine ER as a treatment for postpartum hypertension. |
| Important limitations | Patients with certain heart conditions, asthma, or AV block are excluded. Study treatment escalation is guided by provider discretion, which may affect comparability. | Participants with contraindications to Nifedipine or abnormal heart rates are excluded. Dose escalation and medication adjustment may introduce variability in treatment response. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Until normotension is achieved for at least 12 hours before discharge
Participants receive either Nifedipine XR or Labetalol to control postpartum hypertension with dose adjustments as needed by their primary provider. They are monitored for side effects but are not kept hospitalized for study purposes.
Visits determined by clinical care, no additional study visits required
Duration - 6 months
Participants are followed after discharge with outpatient care as dictated by their provider and contacted at 6 months to assess readmission and emergency room evaluations.
1 phone call at 6 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Todd Lovgren, Brendan Connealy, Ruofan Yao...
https://pubmed.ncbi.nlm.nih.gov/34757235/Todd Lovgren, Brendan Connealy, Ruofan Yao...
https://pubmed.ncbi.nlm.nih.gov/36511111/Nebraska Methodist Health System
Lead Sponsor